Bio Screening Industry News

Archive for March, 2007

March 16, 2007

Labcyte Awarded 28th U. S. Patent Describing Improved HTS Microplates for Low Volume Acoustic Transfer

Sunnyvale, CA, March 15, 2007 – Labcyte Inc. announces the issuance of U.S. Patent 7,185, 969 describing microplates used in high-throughput screening that have low electrical resistance. These plates are more easily electrically grounded than traditional plastic microplates and are more easily de-ionized.

“The trajectory of small droplets can be influenced by electric charges and fields,” said Chief Technical Officer, Richard Ellson. “We deionize both source plates and destinations in our current instruments, the Portrait™ 630 reagent multi-spotter, the Echo® 550 and Echo 555 liquid handlers to reduce this effect. These advances in microplates will reduce the time required for deionization and improve the productivity of the process.”

“The Labcyte acoustic droplet ejection (ADE) technology  used in our award-winning Echo® Series 500 liquid handlers has quickly become the state-of-the-art in sample transfer in high-throughput screening laboratories in the pharmaceutical industry. The technology described in this patent will allow us to increase throughput while expanding the range of available applications.  This invention will also facilitate the placement of arrays onto the bottom of individual wells in multi-well systems. In this case, it is not sufficient to ensure that the compound was simply transferred to a well but that it was transferred to a particular location in the well with no overlap with other compounds transferred. Even a slight charge could force droplets to change trajectory and position of or even move after they land.

These microplates will aid in miniaturization and enable our users to take further advantage of the small drops produced by our acoustic drop ejection technology.

Labcyte Inc., headquartered in Sunnyvale, California, is the world leader in providing acoustic droplet ejection technology for pharmaceutical and life science applications. The award-winning Echo 500 series liquid handlers and Portrait 630 reagent multi-spotters are used in seven of the 10 largest pharmaceutical companies, as well as in leading academic and research institutions and contract research organizations worldwide. The Labcyte acoustic droplet ejection technology has broad applications including compound management, assays, arraying, particle manufacturing, imaging mass spectrometry, and live-cell transfer. Labcyte also provides a range of unique microplate consumables. Labcyte has 28 issued U.S. patents, 3 issued European patents and additional international filings. For more information, visit www.labcyte.com.

La Merie and PharmaPlus team up to provide No-Frills business intelligence solutions

Filed under: Business and Investment, Europe, Press Releases — admin @ 3:11 pm

BARCELONA, Spain and HUIZEN, The Netherlands | Mar 15, 2007 | The Business Intelligence firm La Merie S.L. and the Dutch company PharmaPlus Consultancy BV announced today their collaboration to promote PharmaPlus’ proprietary financial deal database PharmaDeal Financials. The database is available in extracts for specific themes such as Diabetes & Obesity or Big Pharma & Big Biotech. PharmaDeal Financials extracts are unique searchable licensing deal databases. Available as online downloads, the databases contain financial deal specifics including deal size, upfront and milestone payments, royalties on sales, research funding and equity. The databases are fully searchable and provide quick access to financial deal specifics on one screen. PharmaDeal Financials databases allow easy comparison of deal structures with deal history from 1996 on. The products can be obtained on La Merie’s Online Store www.pipelinereview.com.

PharmaDeal Financials complements La Merie’s R&D Competitor Analysis series providing no-frills, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at affordable prices. The information is provided in a tabular format and fully referenced. Competitor projects are described by drug codes, target or mechanism of action, class of compound or product category, company, therapeutic area, indication, R&D stage and additional comments with a hyperlink leading to the source of information. The products of the R&D Competitor Analysis series are elaborated by independent analysts of La Merie Business Intelligence and distributed by PipelineReview.com.

About La Merie

La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide high quality information on research and development to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. PipelineReview.com is the News Center and Online Store of La Merie Business Intelligence. The company’s No-Frills Competitor Analysis series is published in R&D Pipeline News and is also available as individual reports on the site. For more information visit www.pipelinereview.com

About PharmaPlus Consultancy

PharmaPlus Consultancy BV provides services on strategic alliances (licensing), initial market studies and project management for independent researches, universities and start-ups in the biotechnology and pharmaceutical field. Through the use of several internal proprietary databases, the company ensures the commercial exploitation of inventions originating from universities and biopharmaceutical start-ups. For more information visit www.pharmaplus.nl

SOURCE: La Merie Business Intelligence

Powered by WordPress